Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 9/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14432102 | 0.86 | SMN1; SMN2 (0.65) | TP53SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL14543730 | 0.84 | TP53 (0.63) | TP53SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL13815984 | 0.80 | ADORA3 (0.59) | TP53SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL14463535 | 0.77 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL15166672 | 0.77 | ADORA3 (0.56) | TP53SMN1; SMN2MAPTKDM4ENPC1 | |
| SCHEMBL9266107 | 0.76 | ADORA3 (0.58) | TP53SMN1; SMN2MAPTKDM4ENPC1 | |
| SCHEMBL15976546 | 0.74 | ALDH1A1 (1.00) | TP53SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL30881966 | 0.74 | SMN1; SMN2 (0.66) | TP53SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL14916920 | 0.74 | FABP4 (0.62) | SMN1; SMN2MAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL13780323 | 0.73 | ADORA3 (0.57) | SMN1; SMN2MAPTKDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | TP53 117/4885SMN1; SMN2 4254/4885MAPT 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.